A new hope for early gonarthrosis treatment using a biotechnological therapeutic drug to regenerate cartilage by intra-articular knee injection

Project Information

RHYP

Grant agreement ID: 766606

DOI

10.3030/766606

Project closed

EC signature date 31 May 2017

Start date 1 June 2017

End date 30 November 2020

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Total cost

€ 3 008 500,00

EU contribution

€ 2 105 950,00

Coordinated by

REGULAXIS
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (4)

Report on volunteers recruitment and clinical trial launch
Copy of CTA folder
Ethical protocols reports and authorization approval copies
Report to present RHYP corporate identity and first leaflet and promotion material models

Publications

Peer reviewed articles (1)

REG-O3 chimeric peptide combining growth hormone and somatostatin sequences improves joint function and prevents cartilage degradation in rat model of traumatic knee osteoarthritis

Author(s): Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Sébastien Pirson, Thibaut Neutelings, Yves Henrotin, Christelle Vêtu
Published in: PLOS ONE, Issue 15/4, 2020, Page(s) e0231240, ISSN 1932-6203
Publisher: Public Library of Science
DOI: 10.1371/journal.pone.0231240